The Company’s indefinite-lived intangible asset, OncoHist, is in-process research and development relating to the Company’s business combination with SymbioTec in 2012. The carrying value of OncoHist was approximately $9.2 million as of September 30, 2018 and December 31, 2017. No impairment was recorded during the nine months ended September 30, 2018 nor during the year ended December 31, 2017. OncoHist is not yet commercialized and, therefore, has not yet begun to be amortized as of September 30, 2018.